Published in J Drug Deliv on October 13, 2011
Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response. Front Immunol (2015) 1.16
Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1β production in response to β-glucans and the fungal pathogen, Candida albicans. J Immunol (2014) 1.02
Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol (2013) 0.89
Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts. MBio (2015) 0.81
Exploiting fungal cell wall components in vaccines. Semin Immunopathol (2014) 0.80
Duality of β-glucan microparticles: antigen carrier and immunostimulants. Int J Nanomedicine (2016) 0.76
Targeted Delivery of Glucan Particle Encapsulated Gallium Nanoparticles Inhibits HIV Growth in Human Macrophages. J Drug Deliv (2016) 0.76
Preparation and characterization of beta-glucan particles containing a payload of nanoembedded rifabutin for enhanced targeted delivery to macrophages. EXCLI J (2017) 0.75
Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells. Sci Rep (2017) 0.75
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm (2005) 7.53
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Immune recognition. A new receptor for beta-glucans. Nature (2001) 6.54
Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano (2008) 3.88
Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature (2009) 3.21
Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small (2007) 3.05
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res (2007) 3.03
Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release (2007) 2.74
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A (2009) 2.72
Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano (2010) 2.36
Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev (2002) 2.19
Characterization of the human beta -glucan receptor and its alternatively spliced isoforms. J Biol Chem (2001) 2.03
Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Acc Chem Res (2007) 1.96
Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem (2004) 1.57
Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res (1970) 1.50
Nanotechnology-based drug delivery systems. J Occup Med Toxicol (2007) 1.50
Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug Chem (1993) 1.35
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano (2009) 1.29
Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun (2009) 1.29
Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology (2007) 1.27
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem (2004) 1.24
Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug Chem (2008) 1.17
Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J (2011) 1.03
Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol (2008) 0.99
Polysaccharide-oligoamine based conjugates for gene delivery. J Med Chem (2002) 0.94
Biotechnological doxorubicin production: pathway and regulation engineering of strains for enhanced production. Appl Microbiol Biotechnol (2010) 0.91
Determination of degree of substitution of formyl groups in polyaldehyde dextran by the hydroxylamine hydrochloride method. Pharm Res (1991) 0.89
Nanotheranostics: integration of imaging and targeted drug delivery. Mol Pharm (2010) 0.88
Current trends in the application of nanoparticles in drug delivery. Curr Med Chem (2011) 0.88
Multiphoton-absorption-induced-luminescence (MAIL) imaging of tumor-targeted gold nanoparticles. Bioconjug Chem (2010) 0.82
Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors. Mol Pharm (2010) 0.81
Zeta potential mediated reaction monitoring on nano and microparticles. Bioconjug Chem (2011) 0.77
Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature (2009) 3.21
Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol (2004) 2.00
Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res (2003) 1.81
Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun (2009) 1.29
Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio (2010) 1.22
Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug Chem (2008) 1.17
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain (2014) 1.13
Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans. J Immunol (2012) 1.07
Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J (2011) 1.03
Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. MBio (2011) 0.99
Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis. Infect Immun (2012) 0.97
A comparison of the pulmonary inflammatory potential of different components of yeast cell wall. J Toxicol Environ Health A (2007) 0.95
β-Glucan microparticles are good candidates for mucosal antigen delivery in oral vaccination. J Control Release (2013) 0.90
Characterization and optimization of the glucan particle-based vaccine platform. Clin Vaccine Immunol (2013) 0.88
Exploiting fungal cell wall components in vaccines. Semin Immunopathol (2014) 0.80
Targeted Delivery of Glucan Particle Encapsulated Gallium Nanoparticles Inhibits HIV Growth in Human Macrophages. J Drug Deliv (2016) 0.76